Department of Human Metabolism, School of Medicine and Biomedical Science, Beech Hill Road, University of Sheffield, Sheffield S10 2RF, United Kingdom.
J Clin Endocrinol Metab. 2013 Jun;98(6):2383-91. doi: 10.1210/jc.2012-4276. Epub 2013 Apr 30.
Visceral fat is a significant cardiovascular risk factor. Because visceral fat has not been measured systematically in patients with adrenal incidentalomas, we have tested the hypothesis that visceral fat volume may be associated with cutoffs for serum cortisol levels post dexamethasone.
This was a retrospective, cross-sectional study.
The study was conducted at the Endocrine Investigation Unit, University Teaching Hospital.
Seventy-three women and 52 men diagnosed with adrenal incidentalomas and 9 patients with overt Cushing's syndrome participated in this study.
The following was measured for serum cortisol level after dexamethasone suppression and visceral fat ratios: visceral-subcutaneous (V:S) and visceral-total volume (V:TV) measured by computed tomography.
Sixty-eight patients with a postdexamethasone serum cortisol greater than 1.8 μg/dL (50 nmol/L) showed a significantly higher mean V:S and V:TV fat ratio compared with those whose serum cortisol was less than 1.8 μg/dL: women, lnV:S, -0.45 vs -0.69 [mean difference 0.24 (95% confidence interval [CI] 0.08-0.41); P = .004] and V:TV, 0.39 vs 0.34 [mean difference 0.05 (95% CI 0.02-0.09); P = .004]; men, lnV:S, 0.64 vs 0.29 [mean difference 0.35 95% CI 0.08-0.63); P = .01] and V:TV, 0.65 vs 0.57 [mean difference 0.08 (95% CI 0.02-0.14); P = .02]. By ANOVA and post hoc analysis (Fisher's least significant differences), there was no difference in fat ratios between the postdexamethasone serum cortisol groups [1.8-2.9 μg/dL (50-82 nmol/L), 3.0-5.0 μg/dL (83-137 nmol/L), > 5.0 μg/dL (>138 nmol/L) and Cushing's syndrome (mean V:TV: 0.38, 0.40, 0.40, 0.41, respectively)], but they all differed significantly from the less than the 1.8-μg/dL group (V:TV: 0.34, P = .03).
Visceral fat is increased in patients with adrenal incidentalomas and a postdexamethasone serum cortisol of greater than 1.8 μg/dL and is similar to that found in patients with overt Cushing's syndrome.
内脏脂肪是心血管疾病的一个重要危险因素。由于尚未系统地测量过患有肾上腺意外瘤患者的内脏脂肪,因此我们检验了这样一个假设,即内脏脂肪量可能与地塞米松后血清皮质醇水平的切点有关。
这是一项回顾性的、横断面研究。
研究在大学教学医院的内分泌学研究室进行。
73 名女性和 52 名男性被诊断为肾上腺意外瘤,9 名患者患有显性库欣综合征,他们参加了这项研究。
通过计算机断层扫描测量地塞米松抑制后血清皮质醇和内脏脂肪比的变化:内脏-皮下(V:S)和内脏-总容积(V:TV)。
68 名地塞米松后血清皮质醇水平大于 1.8μg/dL(50nmol/L)的患者,其 V:S 和 V:TV 脂肪比显著高于皮质醇水平小于 1.8μg/dL 的患者:女性,lnV:S,-0.45 比-0.69[平均差异 0.24(95%置信区间[CI]0.08-0.41);P=0.004]和 V:TV,0.39 比 0.34[平均差异 0.05(95%CI 0.02-0.09);P=0.004];男性,lnV:S,0.64 比 0.29[平均差异 0.35 95%CI 0.08-0.63);P=0.01]和 V:TV,0.65 比 0.57[平均差异 0.08(95%CI 0.02-0.14);P=0.02]。通过方差分析和事后分析(Fisher 最小显著差异),地塞米松后血清皮质醇组之间的脂肪比没有差异[1.8-2.9μg/dL(50-82nmol/L),3.0-5.0μg/dL(83-137nmol/L),>5.0μg/dL(>138nmol/L)和库欣综合征(平均 V:TV:0.38、0.40、0.40、0.41)],但它们都与 1.8μg/dL 以下的组有显著差异(V:TV:0.34,P=0.03)。
肾上腺意外瘤患者的内脏脂肪增加,地塞米松后血清皮质醇水平大于 1.8μg/dL,与显性库欣综合征患者相似。